SBIO250516C23000
- 0.00
- 0.000.00%
Alps Etf Trust Medical Breakthroughs Etf Newsroom
Rhythm Pharmaceuticals Presents Data On Patients With Acquired Or Congenital Hypothalamic Obesity (N=35) Treated With Setmelanotide For Up To Nine Months In French Early-Access Program
Citigroup Maintains Buy on Akero Therapeutics, Lowers Price Target to $78
Akero Therapeutics Analyst Ratings
U.S. stock market close: The Nasdaq surged over 4%, Chinese concept stocks performed even stronger, and the Golden Dragon Index outperformed the Large Cap.
① High-level economic and trade talks between China and the U.S. exceeded expectations, boosting U.S. stocks; ② Both the S&P and Nasdaq hit new closing highs since March 3; ③ NVIDIA rose over 5%, with its Market Cap returning to above 3 trillion; ④ Trump: Will investigate pharmaceutical companies if necessary.
Akero Therapeutics GAAP EPS of -$0.90 Beats by $0.12
Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028
Joint Statement on U.S.-China Economic and Trade Meeting in Geneva
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68
Akero Therapeutics Publishes Results From Phase 2b SYMMETRY Trial In New England Journal of Medicine; Results Support Potential Benefit Of EFX To Elicit Fibrosis Improvement In Patients With F4 Fibrosis
Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate
Crinetics Pharmaceuticals Q1 EPS $(1.04) Misses $(0.93) Estimate, Sales $361.00K Beat $90.91K Estimate
Wells Fargo Maintains Overweight on Merus, Lowers Price Target to $89
Merus Analyst Ratings
Zai Lab Q1 EPS $(0.04) Beats $(0.55) Estimate, Sales $106.49M Miss $116.76M Estimate
Merus GAAP EPS of -$1.40, Revenue of $26.48M
Rhythm Pharmaceuticals Outlines Q3 2025 Filing for Acquired Hypothalamic Obesity Treatment
Rhythm Pharmaceuticals Analyst Ratings